Commercial Access Agreement Nice
In exceptional cases, a simple system of access to patients at a discount may be accepted at other times in the NICE process. A simple rebate system can be proposed: 4.10 The evaluation committee examines the impact of a proposal for a patient access system on clinical technologies and costs and clarifies relevant points with the company (see section 3.3). The ERG or NICE team assesses the impact of the proposed system on clinical reporting and cost-effectiveness. The market access landscape has changed considerably since the introduction of NICE in 1999 and the regulation of drug prices (PPRS, 2009, updated in 2014). In 2009, PPRS introduced increasingly formalized pricing mechanisms to enable industry to benefit from a number of options, including patient access systems. Patient Access System (PAS): price agreements proposed by pharmaceutical companies to allow patients to access high-cost drugs. at the end of the evaluation process, as soon as all appeals have been heard and THE final NICE guidelines have been provided to the NHS as part of a prompt review of the guidelines. The evaluation procedure could allow for the approval of a complex patient access system, particularly when implemented in response to the technical commitment or CDA. It is the company`s responsibility to ensure that NHS England has sufficient time to complete its review of the patient access system in a timely manner prior to the evaluation committee meeting. 4.18 If, after the publication of an ACD, NHS England authorizes a simple proposal for a discounted patient access system, the impact of the proposed regulation on the cost-effectiveness of the technology may lead the evaluation committee to review its recommendations. If the technology is recommended, a SD is issued for the claim (see section 3.5.44). The information is published to understand the proposed regime and its impact on cost-effectiveness and recommendations. In the absence of consultant complaints, the DSE is the basis of NICE`s technology guidelines.
In certain circumstances, the centre director or program director and the chair of the evaluation committee may decide that a new CDA should be established. If this is the case, the consultation process is repeated. The decision to establish an additional CDA will lengthen the evaluation time. 4.23 The company must use the patient access model to provide details of the proposed system, a revised business model that provides a patient access system and, if applicable, an updated list of confidential information. This is in addition to the information that NHS England must provide as part of a proposal for a proposal on patient protection systems.